Company Announcement
COPENHAGEN, Denmark; February 26, 2024 – Genmab A/S (Nasdaq: GMAB). On February 14, 2024, Genmab announced the initiation of a share buy-back program to honor our commitments under our Restricted Stock Units program.
The share buy-back program is expected to be completed no later than March 15, 2024, and comprises up to 190,000 shares.
The following transactions were executed under the program from February 19 to February 23, 2024:
| No. of shares | Average price (DKK) | Total value (DKK) |
Accumulated through last announcement | 23,000 | | 46,481,960 |
February 19, 2024 | 8,000 | 2,027.41 | 16,219,280 |
February 20, 2024 | 15,000 | 1,995.47 | 29,932,050 |
February 21, 2024 | 16,000 | 1,977.56 | 31,640,960 |
February 22, 2024 | 12,000 | 2,003.14 | 24,037,680 |
February 23, 2024 | 10,000 | 2,003.28 | 20,032,800 |
Total | 61,000 | | 121,862,770 |
Accumulated under the program | 84,000 | | 168,344,730 |
Details of each transaction are included as an appendix to this announcement.
Following these transactions, Genmab holds 819,891 shares as treasury shares, corresponding to 1.24% of the total share capital and voting rights.
The share buy-back program is undertaken in accordance with Regulation (EU) No. 596/2014 (‘MAR’) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the “Safe Harbour Regulation.” Further details on the terms of the share buy-back program can be found in our company announcement no. 06 dated February 14, 2024.
About Genmab
Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For more than 20 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational research and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. To help develop and deliver novel antibody therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with Knock-Your-Socks-Off (KYSO®) antibody medicines.
Established in 1999, Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com and follow us on X.com/Genmab.
